Researchers analyzed data from over 24,000 patients in clinical trials and 400 cases in a safety database to look at CDK4/6 inhibitors. These are a class of medications used to treat both early and advanced breast cancer. The study looked specifically at how these drugs affect the liver, which is a common concern for patients undergoing long-term treatment.
The analysis found that patients taking CDK4/6 inhibitors showed significantly higher rates of liver toxicity compared to those who did not. Specifically, the drugs palbociclib, ribociclib, and abemaciclib were linked to these issues. In contrast, the drug dalpiciclib did not show the same link to liver toxicity in the clinical trials.
While the data shows a clear link between these medications and liver issues, the evidence comes from a mix of controlled trials and a reporting database. Because the data is based on these specific sources, it is important to talk to your doctor about how these findings apply to your specific treatment plan and how they might monitor your liver health.
